TY - JOUR
T1 - Cardiovascular complications of COVID-19
AU - Farshidfar, Farnaz
AU - Koleini, Navid
AU - Ardehali, Hossein
N1 - Funding Information:
HA is supported by NIH grants National Heart, Lung, and Blood Institute HL140973, HL138982, and HL140927 and Leducq Foundation.
Publisher Copyright:
© 2021, Farshidfar et al.
PY - 2021/7/8
Y1 - 2021/7/8
N2 - The emergence of the novel SARS coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has resulted in an unprecedented pandemic that has been accompanied by a global health crisis. Although the lungs are the main organs involved in COVID-19, systemic disease with a wide range of clinical manifestations also develops in patients infected with SARS-CoV-2. One of the major systems affected by this virus is the cardiovascular system. The presence of preexisting cardiovascular disease increases mortality in patients with COVID-19, and cardiovascular injuries, including myocarditis, cardiac rhythm abnormalities, endothelial cell injury, thrombotic events, and myocardial interstitial fibrosis, are observed in some patients with COVID-19. The underlying pathophysiology of COVID-19–associated cardiovascular complications is not fully understood, although direct viral infection of myocardium and cytokine storm have been suggested as possible mechanisms of myocarditis. In this Review, we summarize available data on SARS-CoV-2–related cardiac damage and discuss potential mechanisms of cardiovascular implications of this rapidly spreading virus.
AB - The emergence of the novel SARS coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has resulted in an unprecedented pandemic that has been accompanied by a global health crisis. Although the lungs are the main organs involved in COVID-19, systemic disease with a wide range of clinical manifestations also develops in patients infected with SARS-CoV-2. One of the major systems affected by this virus is the cardiovascular system. The presence of preexisting cardiovascular disease increases mortality in patients with COVID-19, and cardiovascular injuries, including myocarditis, cardiac rhythm abnormalities, endothelial cell injury, thrombotic events, and myocardial interstitial fibrosis, are observed in some patients with COVID-19. The underlying pathophysiology of COVID-19–associated cardiovascular complications is not fully understood, although direct viral infection of myocardium and cytokine storm have been suggested as possible mechanisms of myocarditis. In this Review, we summarize available data on SARS-CoV-2–related cardiac damage and discuss potential mechanisms of cardiovascular implications of this rapidly spreading virus.
UR - http://www.scopus.com/inward/record.url?scp=85109440055&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85109440055&partnerID=8YFLogxK
U2 - 10.1172/jci.insight.148980
DO - 10.1172/jci.insight.148980
M3 - Review article
C2 - 34061779
AN - SCOPUS:85109440055
SN - 2379-3708
VL - 6
JO - JCI Insight
JF - JCI Insight
IS - 13
M1 - e148980
ER -